rovalpituzumab tesirine,Crovalimab
abbvie,roche
['rova,(-approval)', 'rova,(-approval),(-microvascular)', 'dance', 'imab ']
crovalimab, a novel c5 inhibitor for pnh pts - first dose iv, then 4 weekly for 4 weeks then sc every 4 wks - high response rates in terms of hb improvement, ldh normalisation #ash22 
Guidelines, updates, Questions, Meetings in Hematology.